Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
|Videos|July 26, 2017
Dr. Bauml on CAR T-Cell Therapy in Head and Neck Cancer
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses chimeric antigen receptor (CAR) T-cell therapy in head and neck cancer.
There could be a place for CAR T-cell therapy in head and neck cancer, says Bauml, but there are limitations.
Advertisement
Related to this article
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5